Physicians' office, including specialists, Gastronomist, Internal medicine practitioners
Newman Hahn
Inotek Pharmaceuticals is a privately held biotechnology company based in Lexington, MA, focused on the discovery and development of innovative drugs to address serious eye diseases such as glaucoma, ocular hypertension, age-related macular degeneration, and retinal neuropathies. Their lead program, trabodenoson INO-8875, is a highly selective adenosine mimetic that targets the A1 sub-receptor, offering a novel mechanism of action for the treatment of elevated intraocular pressure associated with glaucoma and ocular hypertension. With a deep pipeline of drug candidates, Inotek Pharmaceuticals aims to ameliorate inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for eye disease treatments. Their experienced management team and successful track record in advancing clinical programs towards commercialization position the company to benefit patients and physicians in managing ocular diseases.Generated from the website
